More options are always better, right? Obviously, that’s a “yes” when it comes to building our dream Tesla Model S. But big biopharma is ...

When was the last time a life sciences venture firm spent $50 million all in one go? It doesn't happen often. But in the past week, t...

When was the last time biotech had a really juicy, successful, high-stakes bidding war? Likely the $10.2 billion Pharmasset acquisition...

  For pharmas making all but the largest acquisitions, cash is king. From speculative buyouts of preclinical start-ups all the way throu...

Ever since Merck jumped into the biosimilar field in 2008 with a ferocious go get ’em attitude more fitting of an NFL tackle than a big ...

When it comes to corporate tax planning, biopharmas as a group aren’t spectacularly sophisticated. (A few exceptions come to mind, most no...

Like any conscientious time traveller, a biopharma needs to tread carefully around iterations of its current, past and future deal-making...